Jiangsu wuzhong(SH:600200) Shang Hai Zheng Quan Bao·2025-07-29 17:49Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is experiencing significant stock price fluctuations, with a cumulative decline of over 12% in closing prices over three consecutive trading days, indicating severe abnormal trading conditions [2][4]. Group 1: Stock Trading Abnormalities - The company's stock has shown a cumulative closing price decline of over 12% across three trading days (July 25, July 28, July 29, 2025) [4]. - The stock has exhibited four instances of the same directional abnormal fluctuation within ten trading days, qualifying as severe abnormal trading conditions as per Shanghai Stock Exchange regulations [4]. Group 2: Financial Reporting Issues - The company's 2024 annual financial report received a disclaimer of opinion from the auditing firm, triggering a risk warning for delisting under the Shanghai Stock Exchange rules [3]. - Internal controls over the financial report were also flagged, with related parties of the controlling shareholder identified as having non-operational fund occupation issues [3]. Group 3: Regulatory Actions - On July 13, 2025, the company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for inflating revenue and profits in annual reports from 2020 to 2023, which may lead to mandatory delisting [11]. - The stock has been under a delisting risk warning since July 14, 2025, pending the CSRC's final decision [11]. Group 4: Operational Status - The company has confirmed that, aside from disclosed matters, there have been no significant changes in its daily operations or external environment [5]. - No undisclosed major events, such as asset restructuring or significant business collaborations, have been identified [7]. Group 5: Other Relevant Information - The company is facing potential revenue and profit declines in its medical aesthetics segment due to a termination notice received from Regen Biotech Inc. regarding exclusive agency rights [13]. - As of July 22, 2025, all shares held by the controlling shareholder are under judicial pledge or freeze, indicating potential liquidity issues [13].